Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Schechter Investment Advisors LLC

Schechter Investment Advisors LLC trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 969 shares of the biopharmaceutical company’s stock after selling 13 shares during the quarter. Schechter Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $851,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Sunbelt Securities Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at $26,000. Fortitude Family Office LLC purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. Sutton Wealth Advisors Inc. grew its stake in Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 13 shares during the last quarter. Finally, Bruce G. Allen Investments LLC acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $40,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

REGN has been the subject of a number of research reports. Royal Bank of Canada upped their target price on shares of Regeneron Pharmaceuticals from $1,096.00 to $1,184.00 and gave the company an “outperform” rating in a report on Tuesday, February 27th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 5th. TD Cowen boosted their target price on Regeneron Pharmaceuticals from $900.00 to $1,000.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 6th. Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 6th. Finally, Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $967.59.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,707 shares of the business’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the completion of the transaction, the director now owns 6,382 shares in the company, valued at approximately $6,062,900. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,729 shares of company stock worth $13,124,641. 8.83% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Trading Up 0.3 %

REGN opened at $966.30 on Thursday. The firm’s 50 day moving average is $957.54 and its 200-day moving average is $878.93. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $106.06 billion, a P/E ratio of 27.81, a P/E/G ratio of 2.77 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $10.96 EPS. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.75 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.